Alhemo 15 mg/1.5 ml

Alhemo 15 mg/1.5 ml is a medicine authorised by Swissmedic under authorisation number 68844. The authorisation holder is Novo Nordisk Pharma AG. The medicinal product code is Biotechnological medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 08 August 2023 and the authorisation is limited until 07 August 2028. ATC code B02BX places the medicine in the group Antihemorrhagics.

  • Dispensing category A
  • Authorisation number 68844
  • ATC B02BX
  • Biotechnological medicines
Authorisation data
Authorisation number68844
NameAlhemo 15 mg/1.5 ml
Full nameAlhemo 15 mg/1.5 ml, Injektionslösung im Fertigpen
Authorisation holderNovo Nordisk Pharma AG
Medicinal product codeBiotechnological medicines
Dispensing categoryA · Prescription, not repeatable
ATC codeB02BX
First authorisation08 August 2023
Authorisation validity07 August 2028
Strengths
No.NameDispensing categoryAuthorisation date
1Alhemo 15 mg/1.5 ml, Injektionslösung im FertigpenA08 August 2023
2Alhemo 60 mg/1.5 ml, Injektionslösung im FertigpenA08 August 2023
3Alhemo 150 mg/1.5 ml, Injektionslösung im FertigpenA08 August 2023
4Alhemo 300 mg/3 ml, Injektionslösung im FertigpenA08 August 2023

Scroll the table sideways

Pack sizes
Pack codeQuantityUnitATCIT codeDispensing category
11FertigpenB02BX06.01.1.A
21FertigpenB02BX06.01.1.A
31FertigpenB02BX06.01.1.A
41FertigpenB02BX06.01.1.A

Scroll the table sideways

Other medicines from this authorisation holder

Frequently asked questions

Is Alhemo 15 mg/1.5 ml authorised in Switzerland?

Yes. Alhemo 15 mg/1.5 ml is authorised by Swissmedic under authorisation number 68844, data as of 01 September 2026. The authorisation is limited until 07 August 2028.

Which dispensing category does Alhemo 15 mg/1.5 ml have?

Alhemo 15 mg/1.5 ml is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.

Who is the authorisation holder of Alhemo 15 mg/1.5 ml?

The authorisation holder is Novo Nordisk Pharma AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.

Sources

Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.

Authorisation in Switzerland?

About 2 minutes. No obligation.

First, a little about your business.

Your answers stay in this page until you send your enquiry.

What would you like to achieve?

Your project

Where can we reach you?

You can go back to review your answers before sending.

* Required fields
Prefer email? info@swissmedicinesdirectory.com